O
GEVA

OrbiMed’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

OrbiMed’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-77,800
Closed -$7.22M – 150
2014
Q4 		$7.22M Sell
77,800
-33,300
-30% -$2.63M 0.07% 103
2014
Q3 		$7.64M Hold
111,100
– – 0.08% 104
2014
Q2 		$11.6M Hold
111,100
– – 0.14% 74
2014
Q1 		$9.22M Sell
111,100
-18,900
-15% -$1.75M 0.11% 97
2013
Q4 		$8.41M Hold
130,000
– – 0.12% 85
2013
Q3 		$8.24M Buy
+130,000
New +$6.4M 0.15% 85

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

OrbiMed's GEVA Position: Q1 2015 in Review

OrbiMed sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 77,800 shares — an estimated $7.22M sold.

OrbiMed first reported a position in GEVA in Q3 2013 and held it in 6 quarters. The position peaked at $11.6M in Q2 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • OrbiMed reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • OrbiMed sold 77,800 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $7.22M.
  • OrbiMed first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 6 quarters.
  • OrbiMed's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $11.6M in Q2 2014.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.